Alphabet, Tencent and Gilead Sciences are in line to achieve exits, after the vaccine developer filed to go public on the Nasdaq Global Market.
Vaccitech, a UK-based cancer and infectious disease vaccine developer backed by corporate investors Alphabet, Tencent and Gilead Sciences, filed for an initial public offering in the US on Friday. Financial terms have not yet been set and Vaccitech has used a placeholder $100m target in its draft prospectus. It is looking to list on the…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.